Diabetes is the main cause of peripheral neuropathy. We’re supporting diabetes awareness month by promoting diabetes education. By learning about what can increase your risk of getting diabetes and the signs that show you might have it, you can take steps to prevent it or manage it better. Diabetes facts One in 10 people worldwide …
Does diabetic peripheral neuropathic pain (DPNP) disrupt your daily life and keep you awake at night despite your current treatment? You are not alone. The NEPTUNE-17 clinical trial, hosted by the Foundation for Peripheral Neuropathy Research Impact’s partner, GSK, offers a potential new option for managing DPNP symptoms. You may be eligible to participate in …
Join the NEPTUNE-17 clinical trial for Diabetic Peripheral Neuropathic Pain (DPNP) Read More »
The Foundation for Peripheral Neuropathy (FPN) is delighted to announce that Sandra Rieger, PhD, has joined the Foundation’s Scientific Advisory Board (SAB). The SAB advises both the Board of Directors and staff of the Foundation in areas of science and technology relevant to peripheral neuropathy and its research. Dr. Sandra Rieger earned a Ph.D. in Developmental …
Diabetic peripheral neuropathy (DPN), or nerve damage caused by diabetes, is one of the most known causes of neuropathy. DPN can be a common complication that affects the extremities and normally presents itself as a loss of sensation, most often described as numbness and tingling. Symptoms of DPN can also cause debilitating pain which is …
Speak For Your Feet Contest for Diabetic Peripheral Neuropathy Read More »
More than 37 million people in the U.S. live with diabetes today. 1 And for many of them, nerve damage caused by diabetes – a condition called diabetic peripheral neuropathy or diabetic nerve pain – is a common complication that most often affects the lower extremities and normally presents itself as tingling, numbness, burning, shooting …
A study entitled “Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary” was published on December 29, 2021, in the journal Neurology®. The Foundation for Peripheral Neuropathy (FPN) is pleased to announce that Lindsay Colbert, Executive Director, was among the few esteemed authors on the subcommittee for this important review and update. …
AAN’s New Painful Diabetic Polyneuropathy Guidelines Read More »
Following the Foundation for Peripheral Neuropathy‘s (FPN) recent webinar on current research trends, Lindsay Colbert, FPN’s Executive Director, caught up with the program’s panelists, Dr. Senda Ajroud-Driss, Dr. Ahmet Höke and Dr. Gordon Smith to follow-up on some important questions that the program did not have time to cover. In this “Ask the Expert” series, …
Ask the Expert: Popular Questions from PN Patients Read More »
Erchonia Corporation is currently recruiting for a study on the effect of Low Level Laser Therapy on Diabetic Peripheral Neuropathy pain. This study can be found at ClinicalTrials.gov here. PURPOSE OF THE STUDY In this study, the Sponsor, Erchonia Corporation, and investigators are studying the use of a device called the Erchonia® FX-635™ that gives …
In January 2019, a study was published by the Journal of the Peripheral Nervous System on the design and characteristics of patient data collected from the Peripheral Neuropathy Research Registry (PNRR). This is the first ever overall study performed on this Patient Registry and one that truly highlights the importance of this dataset for current …
Key Data from FPN Patient Registry Highlighted in Top Medical Journal Read More »
Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple Dose Study to Assess the Efficacy and Safety of NYX-2925 in Subjects with Neuropathic Pain Associated with Diabetic Peripheral Neuropathy. Aptinyx Inc. is conducting a research study evaluating multiple doses of its investigational drug NYX-2925 versus placebo in treating the neuropathic pain associated with diabetic peripheral neuropathy. Enrollment into this …
Research Study for Painful Diabetic Peripheral Neuropathy Read More »
